The Rogosin Institute Plans For Possible Expansion, New Jobs

The Rogosin Institute Plans For Possible Expansion, New Jobs

December 4, 2014

By Riley McDermid, BioSpace.com Breaking News Editor

Ohio nonprofit treatment and research center The Rogosin Institute was reported Thursday to be considering a massive new $14 million expansion that could mean two dozen new biotech jobs brought to the Xenia area, with the possibility of hundreds more over the project’s lifespan.

New York-based Rogosin currently focuses on treatments for kidney disease and diabetes. It said in development plans filed with local officials and that it would like to expand its existing space to add a new production facility for a cancer-specific cellular medical device.

As part of that process, the institute would add at least 25 new jobs initially, with additional projections from the Dayton Development Coalition theorizing as many as 1,000 jobs could be involved in the project’s creation. The institute did not provide comment confirming or denying the plan.

Rogosin currently has 30 employees in a 15,000-square-foot building in Greene County. The county is keen to help the company stay in the area, with documents showing it is seeking $5 million in federal funds to help with the expansion, though officials queried by the Dayton Business Times refused to provide additional details.

The institute is nearing completion of clinical trials in multiple lab facilities, including Ohio State University, and its aim so far to find cellular-level treatments for kidney disease and diabetes appears to have sparked quite a bit of interest from the local scientific community.

The Dayton Business Times reported that the area’s Priority Development and Advocacy Committee, a group of business and community leaders convened by the Dayton Development Coalition, will be heavily involved in any potential expansion. The agency “collects and prioritizes requests for federal funding that supports local projects” and provides an advocacy platform for local businesses.

Back to news